Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy With or Without Consolidation Chemotherapy in Rectal Cancer
NCT03957733Phase 3Unknown
- Sponsor
- King Abdullah Medical City
- Start
- Nov 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FOLFOX and Capecitabine + oxaliplatin in rectal cancer (2 arms), sponsored by King Abdullah Medical City. Primary endpoints: Pathologic Complete Response Rate at 3 years and Disease Free Survival Rate at 3 years. Status: unknown.
02
Drugs
FOLFOXCapecitabine + oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03957733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957733.